In August 2017, the Company entered into a Development and License Agreement with ActiveSite Pharmaceuticals, Inc. pursuant to which the Company acquired the rights to ActiveSite’s Plasma Kallikrein …
The Company will be required, upon the future commercialization of ersodetug, to pay royalties to XOMA based on the net sales of the related products and additional milestone payments to XOMA up to $…
Reciprocal relationship from XOMA graph: Reciprocal relationship from RZLT graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from RZLT graph: The Company will be required, upon …
In December 2017, the Company entered into a license agreement with XOMA Corporation, through its wholly-owned subsidiary, XOMA (U.S.) LLC, pursuant to which XOMA granted an exclusive global license …
The Handok License is in effect for a period of 20 years after the first commercial sale of each product and requires the Company will sell products ordered by Handok at a transfer price equal to 70 …
Rezolute, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RZLT-DEBT-12340
Warrants outstanding: 500000
90%
xbrl warrant detail from xbrl 2023-09-30.
RZLT-DEBT
Debt stack $1.1M
90%
Market cache reports total debt of $1.1M.
RZLT-DEBT-12341
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2019-06-30.
Rezolute, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Rezolute, Inc..
Rezolute, Inc. Ownership
Holder
Name
Confidence
Evidence
RZLT-OWNER-FEDERATED-HERMES-INC
FEDERATED HERMES, INC.
90%
13F overlay lists FEDERATED HERMES, INC. as top holder; 127 tracked holders.
